Fusion Proteins Or Polypeptides Patents (Class 435/69.7)
-
Publication number: 20150072368Abstract: Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium.Type: ApplicationFiled: February 8, 2013Publication date: March 12, 2015Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Alexandre Fontayne, François Coutard
-
Patent number: 8975042Abstract: The field of this invention relates to methods for combining genetic elements such that the activity of one of the elements provides a means for identifying, enriching, selecting for, or enhancing the activity of a second element. The invention also includes specific elements and combinations of elements.Type: GrantFiled: March 8, 2013Date of Patent: March 10, 2015Assignee: DNA Twopointo, Inc.Inventors: Jeremy Minshull, Elias Theodorou
-
Patent number: 8975041Abstract: The present invention relates to novel Prolipase-Bovine trypsinogen (PLBTR) fusion proteins, the genes encoding them, and the production and uses thereof. More specifically, the present invention relates to methods of producing in optimal quantities PLBTR fusion proteins which comprise a heterologous polypeptide which is normally susceptible to autocatalytic activity. More particularly, the present invention relates to fusion proteins which comprise an heterologous polypeptide, such as a serine protease, fused to a lipase signal sequence, which can be expressed by recombinant host cells in desired amounts. The present invention further relates to polynucleotides encoding such fusion proteins, to expression vectors for expression of such fusion proteins, to host cells transformed with such polynucleotides/vectors, and to methods of generating such fusion proteins.Type: GrantFiled: October 26, 2009Date of Patent: March 10, 2015Assignee: Biocon LimitedInventors: Nagaraj Govindappa, Nandini Nataraj, Sanjay Tiwari, Partha Hazra, Mukesh Babuappa Patale, Gokul Jothiraman, Kedarnath Sastry
-
Patent number: 8975384Abstract: The present invention provides a tag peptide comprising an amino acid sequence represented by the following formula (I): X1-Tyr-X2-Gly-Gln-X3??(I) (wherein X1, X2 and X3 are the same or different and each represent any amino acid residue) and an antibody against the tag peptide. By combined use of the tag peptide and antibody of the present invention, a system that enables proteins expressed from cloned genes to be highly purified in an inexpensive and easy manner can be established.Type: GrantFiled: December 18, 2008Date of Patent: March 10, 2015Assignee: Osaka UniversityInventor: Junichi Takagi
-
Patent number: 8968728Abstract: New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.Type: GrantFiled: May 11, 2007Date of Patent: March 3, 2015Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Kandaswamy Sumathy
-
Patent number: 8962295Abstract: The present disclosure relates to CBH I chimera fusion polypeptides, nucleic acids encoding the polypeptides, and host cells for producing the polypeptides.Type: GrantFiled: June 1, 2011Date of Patent: February 24, 2015Assignee: California Institute of TechnologyInventors: Frances H. Arnold, Pete Heinzelman
-
Publication number: 20150051374Abstract: The present disclosure pertains to methods of producing recombinant peptides that contain between 10 and 200 amino acid residues using novel carrier proteins derived from superfolder green fluorescent protein and its mutants.Type: ApplicationFiled: March 25, 2013Publication date: February 19, 2015Inventors: Wenshe Liu, Wei Wan
-
Patent number: 8957021Abstract: The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions.Type: GrantFiled: June 8, 2010Date of Patent: February 17, 2015Assignee: Amunix Operating Inc.Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland
-
Patent number: 8956848Abstract: A UBP1 protease mutant and the sequence coding it, their application and products and the methods used to produce them may be used in the production of recombinant proteins, particularly on an industrial scale.Type: GrantFiled: November 1, 2005Date of Patent: February 17, 2015Assignee: Instytut Biotechnoloii I AntybiotykowInventors: Andrzej Plucienniczak, Anna Wojtowicz, Diana Mikiewicz-Sygula, Grazyna Plucienniczak
-
Patent number: 8956604Abstract: Conjugates comprising a N-oxime bond are disclosed. In one embodiment, a suitable conjugate is represented by the following Formula (I): wherein R? is derived from a compound comprising at least one reactive amide group, R? is derived from a compound comprising at least one reactive aminooxy group, and X is H, CnH(n+2) or other atoms. Additional methods are also provided.Type: GrantFiled: December 21, 2012Date of Patent: February 17, 2015Assignee: The University of KansasInventors: Cory Berkland, Joshua Sestak
-
Publication number: 20150044689Abstract: The invention relates to an isolated or recombinant protein from the shark Heterodontus francisci, which has bovine-erythrocyte-recognition activity and which can bind to sequences of antigens and/or proteins that are characteristic of infectious diseases. Once the aforementioned protein is bound to specific antigens of infectious diseases, it can haemagglutinate upon recognizing the bovine erythrocytes and antibodies characteristic of said diseases, which are present in the active state in biological samples such as whole blood, plasma or serum of bovine origin. The invention also relates to methods for protecting the detection of antibodies characteristic of infectious diseases, using the purified periplasmic extract or fusion protein, optionally purifying the recombinant protein.Type: ApplicationFiled: February 21, 2013Publication date: February 12, 2015Inventors: Alexei Fedorovish Licea Navarro, Jose Felix Olivares Quintero, Ana Paola Gutierrez Ordonez
-
Patent number: 8951972Abstract: Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.Type: GrantFiled: November 14, 2011Date of Patent: February 10, 2015Assignee: Five Prime Therapeutics, Inc.Inventors: Li Long, Thomas Brennan
-
Patent number: 8951756Abstract: A method for cultivating a bacterial cell comprising the addition of an amino acid in an alkaline solution used for pH regulation. Also an aspect is a method for producing a polypeptide comprising the steps of a) providing a bacterial cell comprising a nucleic acid encoding the polypeptide, b) cultivating the provided cell, c) adjusting the pH value during the cultivating with a basic solution comprising an amino acid, d) recovering the polypeptide from the cell or the cultivation medium and thereby producing the polypeptide.Type: GrantFiled: August 25, 2011Date of Patent: February 10, 2015Assignee: Hoffmann-La Roche Inc.Inventor: Christian Schantz
-
Patent number: 8951966Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.Type: GrantFiled: June 29, 2012Date of Patent: February 10, 2015Assignee: NGM Biopharmaceuticals, Inc.Inventors: Lei Ling, Darrin A. Lindhout
-
Patent number: 8951534Abstract: The invention relates to therapeutic vaccines for the treatment of neoplasias caused by the human papillomavirus (HPV). In particular, the vaccines of the present invention are formed by chimeric virus-like capsids of birnavirus containing papillomavirus antigens.Type: GrantFiled: November 5, 2010Date of Patent: February 10, 2015Assignee: Chimera Pharma, S.L.UInventors: Thomas Zurcher, Cayetano Von Kobbe, Juan J. Bernal, Ignacio Jiménez Torres, Gloria Calderita Lucas, Margarita Rodriguez Garcia, Ana Garzon Gutierrez, Virginia Gondar Sousa E Silva, Arcadio García De Castro, Irene Pino De La Huerga
-
Patent number: 8951962Abstract: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.Type: GrantFiled: May 17, 2013Date of Patent: February 10, 2015Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Karthryn S. Prickett, Andrew A. Young
-
Patent number: 8945867Abstract: The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2/0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent.Type: GrantFiled: February 2, 2009Date of Patent: February 3, 2015Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Tatsuya Ogawa, Yoshinobu Konno, Naohisa Akashi, Hiroshi Takasugi, Seiji Sugimoto, Keiichi Yano
-
Patent number: 8945528Abstract: This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by hepatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.Type: GrantFiled: August 30, 2011Date of Patent: February 3, 2015Assignee: Generon (Shanghai) Corporation Ltd.Inventors: Xiaoqiang Yan, Zhihua Huang, Hongzhou Yang, Yuliang Huang
-
Patent number: 8945876Abstract: Embodiments herein include methods and constructs that can be used to co-express two or more polypeptides of interest from a single polynucleotide encoding a precursor polypeptide. Within this precursor polypeptide can reside at least one autonomous processing unit, which can mediate release of flanking polypeptides of interest in cis. The processing unit can include an N-terminal autocatalytic cleavage domain and a C-terminal cleavage domain. Some embodiments include constructs and methods for co-expressing polypeptides without N- or C-terminal overhangs, in any cellular or extracellular location, and/or in stoichiometric ratios.Type: GrantFiled: November 21, 2012Date of Patent: February 3, 2015Assignee: University of HawaiiInventors: Wei Wen Su, Bei Zhang
-
Patent number: 8945877Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density and strength. In certain embodiments, the present invention provides ALK3 polypeptides, including ALK3-Fc fusion proteins.Type: GrantFiled: December 21, 2012Date of Patent: February 3, 2015Assignee: Acceleron Pharma, Inc.Inventor: Jasbir Seehra
-
Publication number: 20150030593Abstract: The disclosure relates to penetration-enhanced targeted proteins and their uses for therapeutics delivery.Type: ApplicationFiled: March 14, 2014Publication date: January 29, 2015Applicant: PERMEON BIOLOGICS, INC.Inventors: Katherine S. Bowdish, James S. Huston, Erik M. Vogan
-
Patent number: 8940288Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.Type: GrantFiled: February 8, 2012Date of Patent: January 27, 2015Assignee: University of ConnecticutInventors: Leo Lefrancois, Thomas A. Stoklasek
-
Publication number: 20150023932Abstract: The present invention provides an intercellular protein delivery system comprising an engineered peptide (EP), composed of secretion part (SP) and nuclear translocation part (NTP), a functional or therapeutic protein (FP), cells that express the fusion proteins and cells that accept the fusion proteins. The system can be used in vivo or in vitro to sustainably supply proteins of interest for cellular reprogramming, cellular differentiation and cell-based protein therapies.Type: ApplicationFiled: July 17, 2013Publication date: January 22, 2015Inventors: KE-KE FAN, Jing Bian
-
Publication number: 20150018521Abstract: The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.Type: ApplicationFiled: February 28, 2014Publication date: January 15, 2015Applicant: Intrexon CorporationInventor: Thomas D. REED
-
Publication number: 20150017685Abstract: The present invention relates to processes for the production of peptides, and the peptides produced accordingly. Peptides produced according to the invention may be produced more efficiently than peptides produced according to prior art processes. The production process of the invention may lead to advantages in yield, purity, and/or price. Methods of marketing peptides are also disclosed.Type: ApplicationFiled: July 8, 2014Publication date: January 15, 2015Inventors: Michael H. B. Stowell, Jonathan Caruthers, Travis Nemkov, Brian Hiester, Leslie Boux, Mikhail Plam
-
Patent number: 8932589Abstract: The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.Type: GrantFiled: March 12, 2013Date of Patent: January 13, 2015Assignee: Novartis AGInventors: David Glass, Shou-Ih Hu
-
Patent number: 8932598Abstract: Compositions that include a fusion protein comprising flagellin and at least one antigen that has an isoelectric point greater than about 7.0 and that is fused to at least one domain 3 of the flagellin activate Toll-like Receptor 5. Methods of stimulating an immune response, in particular, a protective immune response include administering a composition that includes an antigen fused to a loop of domain 3 of flagellin.Type: GrantFiled: June 28, 2013Date of Patent: January 13, 2015Assignee: VaxInnate CorporationInventors: Langzhou Song, Ge Liu, Scott Umlauf, Uma Kavita, Hong Li, Xiangyu Liu, Bruce Weaver, Lynda Tussey
-
Patent number: 8933034Abstract: Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin.Type: GrantFiled: April 18, 2013Date of Patent: January 13, 2015Assignee: Brain-Gen BiotechInventor: Byron D. Ford
-
Patent number: 8932830Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 2, 2012Date of Patent: January 13, 2015Assignee: Biogen Idec Hemophilia, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
-
Publication number: 20150010947Abstract: Methods and systems for creating a genetic construct, a protein, and a polymer comprising a domain swapping module. A domain swapping module is a fusion protein in which a lever protein, which has a long amino (N) to carboxy (C) terminal distance, is inserted into a surface loop of an assembler protein, thereby stretching the assembler protein and splitting it into two fragments held apart by the lever so that they cannot rejoin. If the assembler protein is split at the proper location, the fragments will recombine with their respective counterparts from either one or more different—but similarly-split—assembler proteins.Type: ApplicationFiled: December 27, 2012Publication date: January 8, 2015Applicant: The Research Foundation For The State University Of New YorkInventors: Stewart Loh, Jeung-hio Ha, Diana Mitrea
-
Patent number: 8927232Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.Type: GrantFiled: December 11, 2009Date of Patent: January 6, 2015Assignee: Korea Advanced Institute of Science and Technology (KAIST)Inventors: Keehoon Jung, Young Jun Koh, Gyun Min Lee, Sun Chang Kim, Gou Young Koh
-
Patent number: 8927233Abstract: A fusion polypeptide comprising (A)x-M-(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.Type: GrantFiled: April 5, 2013Date of Patent: January 6, 2015Assignee: Regeneron Pharmaceuticals, Inc.Inventors: James P. Fandl, Gang Chen, Nicholas J. Papadopoulos, Thomas H. Aldrich
-
Patent number: 8927225Abstract: Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim.Type: GrantFiled: September 8, 2009Date of Patent: January 6, 2015Assignee: The University of Hong KongInventors: Shu Leong Ho, Wing Lok Ho, David Boyer Ramsden
-
Publication number: 20150005233Abstract: This invention provides compounds, compositions, and methods for treating hypogly.Type: ApplicationFiled: February 8, 2013Publication date: January 1, 2015Applicant: Seneb Biosciences, Inc.Inventor: Shawn DeFrees
-
Patent number: 8921316Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.Type: GrantFiled: June 4, 2013Date of Patent: December 30, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Daniel Dix, Kelly Frye, Susan Kautz
-
Patent number: 8921097Abstract: The present invention relates to a method of expressing an immunotoxin in Pichia pastoris strain mutated to toxin resistance comprising a) growing the Pichia pastoris in a growth medium comprising an enzymatic digest of protein and yeast extract and maintaining a dissolved oxygen concentration at 40% and above; and b) performing methanol induction with a limited methanol feed of 0.5-0.75 ml/min/IO L of initial volume during induction along with a continuous infusion of yeast extract at a temperature below 17.5° C., antifoaming agent supplied up to 0.07%, agitation reduced to 400 RPM, and the induction phase extended out to 163 h.Type: GrantFiled: November 30, 2010Date of Patent: December 30, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: David M. Neville, Jr., Jung-Hee Woo, Yuan-Yi Liu
-
Patent number: 8920798Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: GrantFiled: November 20, 2012Date of Patent: December 30, 2014Assignee: Amgen Inc.Inventors: Huiquan Han, Hosung Min, Thomas Charles Boone
-
Publication number: 20140371426Abstract: The present invention provides, in one aspect, a method for producing Apolipoprotein in a plant comprising incubating or growing a plant comprising a nucleic acid construct comprising, consisting or consisting essentially of a nucleic acid sequence encoding an Apolipoprotein fusion protein that comprises a fusion protein partner that induces the formation of a protein body in a plant, preferably, wherein the nucleic acid construct is introduced or infiltrated into the plant prior to the incubating or growing step.Type: ApplicationFiled: December 21, 2011Publication date: December 18, 2014Applicant: PHILIP MORRIS PRODUCTS S.A.Inventors: Karen Oishi, Manuel Peitsch
-
Patent number: 8912145Abstract: A vaccine composition for prophylaxis and/or therapy of Alzheimer's disease, which comprises a fusion protein prepared by inserting a single or tandemly repeated multiple copies of amyloid ? antigenic peptide having 5 to 15 continuous amino acid residues derived from the N-terminus of amyloid ? peptide into a wild type seed storage protein.Type: GrantFiled: November 7, 2011Date of Patent: December 16, 2014Assignee: Hokko Chemical Industry Co., Ltd.Inventors: Teruhiko Terakawa, Hisakazu Hasegawa, Yasushi Shimada, Atsushi Takahashi, Takeshi Kawarabayashi, Mikio Shoji
-
Patent number: 8911746Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.Type: GrantFiled: March 12, 2013Date of Patent: December 16, 2014Assignee: Infectious Disease Research InstituteInventors: Yasuyuki Goto, Steven G. Reed
-
Publication number: 20140356910Abstract: The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.Type: ApplicationFiled: May 29, 2014Publication date: December 4, 2014Applicant: AMGEN INC.Inventors: Chung-Jr HUANG, Xiaoming YANG
-
Patent number: 8900827Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 2, 2012Date of Patent: December 2, 2014Assignee: Biogen Idec Hemophilia, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
-
Publication number: 20140349343Abstract: The present disclosure provides a method to express and purify polypeptides and proteins. In the present disclosure the use of lysozyme as a fusion partner is disclosed. Furthermore, purification methods to isolate lysozyme-tagged polypeptides and proteins via lysozyme-specific antibodies are described. More specifically, the present disclosure provides a method to express and purify monomeric polypeptides and proteins by using lysozyme as a tag.Type: ApplicationFiled: January 23, 2013Publication date: November 27, 2014Inventors: Stefan Haertle, Sebastian Jaeger, Daniela Daubert
-
Publication number: 20140348817Abstract: Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided.Type: ApplicationFiled: August 14, 2014Publication date: November 27, 2014Inventors: Ping Jiang, H. Michael Shepard, Lei Huang
-
Publication number: 20140348904Abstract: The present invention relates to exosomes comprising a transferrin targeting moiety on their surface, methods of producing them and to the use of such exosomes for delivering genetic material and/or biotherapeutic proteins or peptides or chemotherapeutic agents in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing, or delivery of other therapeutic agents.Type: ApplicationFiled: December 7, 2012Publication date: November 27, 2014Inventors: Matthew Wood, Samira Lakhal-Littleton, Samir El Andaloussi
-
Patent number: 8895002Abstract: The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins. Also provided are methods for treating iron-related disorders which include administration of a HJV fusion protein to a patient in need thereof.Type: GrantFiled: April 9, 2008Date of Patent: November 25, 2014Assignee: The General Hospital CorporationInventors: Herbert Y. Lin, Jodie Babitt, Clifford J. Woolf, Tarek A. Samad
-
Patent number: 8895012Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.Type: GrantFiled: June 29, 2007Date of Patent: November 25, 2014Assignee: Conaris Research Institute AGInventors: Georg H. Wätzig, Dirk Seegert
-
Patent number: 8895284Abstract: The invention provides histone deacetylase class II nucleic acids and polypeptides, methods and reagents for their use, and related compounds including small molecule libraries containing class II histone deacetylase inhibitors.Type: GrantFiled: May 7, 2013Date of Patent: November 25, 2014Assignee: President and Fellows of Harvard CollegeInventors: Christina M. Grozinger, Christian A. Hassig, Stuart L. Schreiber
-
Publication number: 20140343249Abstract: A cell-killing peptide, more specifically a cell-killing CKP fusion peptide (CTD7:CKP) is disclosed, wherein a cell-killing peptide (CKP) comprising 10 amino acids in MTD of Noxa protein causing cell death, and 7 amino acids targeting a cancer cell are fused. The cell-killing CKP fusion peptide induces strong cell necrosis at various cancer cell lines (HeLa, HCT116, MCF-7, A549, BJAB, CT26, PC3 and the like) and shows strong tumor regression effect at a mouse tumor model using experimental animals, but does not show apoptosis at normal cells. Therefore, it can be broadly used to human body for treating various diseases requiring cell death, particularly, as an anti-cancer drug.Type: ApplicationFiled: December 15, 2011Publication date: November 20, 2014Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITYInventors: Tae-Hyoung Kim, Ae Ran Moon, Ji Young Kim
-
Patent number: 8889377Abstract: Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising, from N-terminus to C-terminus: a) a first portion of a family C G-protein coupled receptor (GPCR), wherein the first portion comprises the TM1, TM2 and TM3, regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, wherein the second portion comprises the TM4, TM5 TM6 and TM7 regions of the GPCR.Type: GrantFiled: May 16, 2013Date of Patent: November 18, 2014Assignee: ConfometRx, Inc.Inventor: Brian Kobilka